SHYFT Analytics and Medidata have announced a partnership that will increase access to healthcare data analytics in clinical trials.
Using SHYFT’s intelligent analytics and Medidata’s clinical technology platform, the partnership will enable life sciences companies to add real world evidence data from electronic medical records and health claims to information collected in clinical trials, providing a more comprehensive view of patient health.
The most important result of this partnership will be that the real world evidence data will improve study design and site selection, two of the most critical and costly components of drug development programs. The partnership will support efforts to design more effective study protocols, more efficiently recruit participants, and uncover the best treatment paths in clinical practice.
Medidata, having worked with more than 700 life sciences customers, has amassed one of the largest sets of clinical data assets in the world. SHYFT’s real world evidence capabilities will provide the life sciences industry with unparalleled healthcare analytics. The partnership became official shortly after the recent completion of SHYFT’s Series B investment round, which included investments from McKesson Ventures and other healthcare industry leaders.
Read more about the partnership between SHYFT and Medidata here.